Key terms
About PHAR
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PHAR news
Apr 08
10:05am ET
Optimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market Expansion
Apr 08
6:58am ET
Pharming Completes Trial Enrollment for Pediatric Drug
Apr 05
2:01am ET
Joenja’s Journey: Navigating the Market Risks and Regulatory Challenges Post-Approval for Pharming Group Nv
Apr 04
8:57am ET
Pharming Group Files Annual Report, Sets AGM Date
Mar 18
5:05am ET
Pharming Group’s Strong Performance and Growth Prospects Justify Buy Rating
Mar 15
3:10pm ET
Pharming Group price target raised to EUR 1.85 from EUR 1.75 at RBC Capital
Mar 14
11:35am ET
Pharming Group’s Strong Financial Performance and Growth Potential Merit Buy Rating
Feb 15
3:01pm ET
Pharming Group price target lowered to EUR 1.75 from EUR 2.10 at RBC Capital
No recent press releases are available for PHAR
PHAR Financials
Key terms
Ad Feedback
PHAR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PHAR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
